Who
Richard Gaynor
Director
Company insider
Files Form 4 as: Director, Zai Lab; Director, Alkermes; Director, Infinity Pharmaceuticals; President of R&D, Neon Therapeutics.
In numbers
- Trades disclosed
- 84
- Buys
- 2
- Sells
- 5
- Bought
- $132K
- Sold
- $222K
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 27 Feb 2019
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 6 Jul 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Bought | $33K1,736 at $19.05 | filing |
| 1 Jul 2026filed 6 Jul 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Bought | $33K1,736 at $19.05 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —22,371 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —22,371 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 17 Mar 2026filed 19 Mar 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Bought | $33K1,731 at $18.91 | filing |
| 17 Mar 2026filed 19 Mar 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Bought | $33K1,731 at $18.91 | filing |
News
No headline names them, or the companies they trade most, lately.